https://www.selleckchem.com/pr....oducts/mi-773-sar405
After a median follow-up of 11 months, 223 (20%) of the overall cohort died/were delisted for sickness. The cumulative incidence of death/delisting increased by worsening ΔLFI group. In competing risk regression adjusted for baseline LFI, age, height, MELDNa, and albumin, a 0.1 unit change in ΔLFI per 3 months was associated with a 2.04-fold increased risk of death/delisting (95% CI, 1.35-3.09). CONCLUSION Changes in frailty were significantly associated with death/delisting independent of baseline frailty and MELDNa. Notably,
Me gusta
Comentario
Compartir
